Canjin Halittar ROS1 na Dan Adam

ROS1 wani nau'in tyrosine kinase ne na transmembrane na dangin masu karɓar insulin. An tabbatar da cewa kwayar halittar ROS1 ta haɗu a matsayin wata muhimmiyar kwayar halittar da ke haifar da cutar kansar huhu wacce ba ta da ƙaramin ƙwayar halitta. A matsayinta na wakilin wani sabon nau'in kwayar halitta ta musamman, yawan kamuwa da kwayar halittar ROS1 a cikin NSCLC. Kimanin kashi 1% zuwa 2% na ROS1 galibi yana yin sake fasalin kwayar halitta a cikin exons 32, 34, 35 da 36. Bayan an haɗa shi da kwayoyin halitta kamar CD74, EZR, SLC34A2, da SDC4, zai ci gaba da kunna yankin ROS1 tyrosine kinase. ROS1 kinase da aka kunna ba bisa ƙa'ida ba zai iya kunna hanyoyin sigina na ƙasa kamar RAS/MAPK/ERK, PI3K/Akt/mTOR, da JAK3/STAT3, don haka yana shiga cikin yaduwa, bambancewa da metastasis na ƙwayoyin ƙari, da kuma haifar da ciwon daji. Daga cikin maye gurbi na haɗin ROS1, CD74-ROS1 ya kai kusan kashi 42%, EZR ya kai kusan kashi 15%, SLC34A2 ya kai kusan kashi 12%, kuma SDC4 ya kai kusan kashi 7%. Bincike ya nuna cewa wurin ɗaure ATP na yankin catalytic na ROS1 kinase da wurin ɗaure ATP na ALK kinase suna da daidaituwa har zuwa kashi 77%, don haka crizotinib na ƙaramin ƙwayar ALK tyrosine kinase da sauransu suna da tasirin warkarwa a bayyane a cikin maganin NSCLC tare da maye gurbi na haɗin ROS1. Saboda haka, gano maye gurbi na haɗin ROS1 shine ginshiƙi kuma tushen jagorantar amfani da magungunan crizotinib.